Acting On Ester Bond (3.1) Patents (Class 435/196)
  • Patent number: 11268076
    Abstract: The present invention relates to a variant of a parent lipase, which parent lipase has the amino acid sequence of SEQ ID NO: 2, wherein the variant has lipase activity, comprises a substitution at a position corresponding to position 51 and comprises a substitution or remains unaltered at a position corresponding to position 96 of SEQ ID NO: 2. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: March 8, 2022
    Assignee: Novozymes A/S
    Inventors: Christian Lundager Gylstorff, Christian Jackel, Jesper Vind, Allan Svendsen, Marco Malten, Thomas Agersten Poulsen
  • Patent number: 11214781
    Abstract: The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: January 4, 2022
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts
  • Patent number: 11203750
    Abstract: This disclosure relates to analyzing the end-to-end sequence and the relative distributions in heterogeneous mixtures of polynucleotides and methods and enabling reagents related thereto.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: December 21, 2021
    Assignees: Emory University, The Johns Hopkins University
    Inventors: Mark C. Emerick, William S. Agnew
  • Patent number: 11168117
    Abstract: The invention relates to an isolated nucleic acid sequence comprising a promoter, which is a native sequence of Pichia pastoris comprising the nucleic acid sequence of pCS1 of SEQ ID 1, or a functionally active variant thereof which is a size variant, a mutant or hybrid of SEQ ID 1, or a combination thereof, expression constructs and recombinant host cells comprising the promoter, and a method of producing a protein of interest under the control of the promoter. It further relates to a method to identify a constitutive promoter from eukaryotic cells, and an isolated nucleic acid sequence comprising a promoter which when operatively linked to a nucleotide sequence encoding a protein of interest directs the expression thereof in a host cell at an expression level that is higher than under control of the native pGAP promoter at high and low growth rates.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 9, 2021
    Assignee: LONZA LTD
    Inventors: Diethard Mattanovich, Brigitte Gasser, Roland Prielhofer
  • Patent number: 11149289
    Abstract: The present invention relates to a nucleic acid molecule encoding (I) a polypeptide having the activity of an endonuclease, which is (a) a nucleic acid molecule encoding a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1; (b) a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO: 2; (c) a nucleic acid molecule encoding an endonuclease, the amino acid sequence of which is at least 70% identical to the amino acid sequence of SEQ ID NO: 1; (d) a nucleic acid molecule comprising or consisting of a nucleotide sequence which is at least 50% identical to the nucleotide sequence of SEQ ID NO: 2; (e) a nucleic acid molecule which is degenerate with respect to the nucleic acid molecule of (d); or (f) a nucleic acid molecule corresponding to the nucleic acid molecule of any one of (a) to (e) wherein T is replaced by U; (II) a fragment of the polypeptide of (I) having the activity of an endonuclease.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 19, 2021
    Assignee: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
    Inventor: Ralf Kühn
  • Patent number: 11142544
    Abstract: A novel substrate-bound DNAzyme complex is provided comprising a DNAzyme bound to a nucleic acid-based substrate. The DNAzyme comprises a pair of binding arms which hybridize to binding regions on the substrate, and a catalytic domain between the binding arms. The nucleic acid-based substrate comprises a phosphorothioate-modified ribonucleotide cleavage site between the binding regions of the substrate. The catalytic domain of the DNAzyme catalyzes heavy metal-dependent cleavage of the substrate cleavage site. The DNAzyme complex is useful in a method of heavy metal sensing. A novel cadmium-selective DNAzyme is also described for cadmium sensing.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: October 12, 2021
    Inventors: Juewen Liu, Po-Jung Jimmy Huang
  • Patent number: 11111508
    Abstract: The invention features Cas9 fusion polypeptides. In one embodiment of the invention, Cas9 is fused to a SNAP tag that enhances Cas9's gene repair function.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 7, 2021
    Assignee: BRANDEIS UNIVERSITY
    Inventor: Nelson Lau
  • Patent number: 11078470
    Abstract: It is an object of the present invention to provide a novel enzyme useful for producing low-purine foods or beverages. There is disclosed a nucleosidase comprising an amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having 85% or more identity with the amino acid sequence, or an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having 88% or more identity with the amino acid sequence.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: August 3, 2021
    Assignees: AMANO ENZYME INC., SUNTORY HOLDINGS LIMITED
    Inventors: Keita Okuda, Toru Katase, Yuko Kuritani, Naoki Matsumoto, Tomoko Fujimura, Ikuma Mizuguchi, Takako Inui
  • Patent number: 10987410
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 27, 2021
    Assignee: Synthetic Biologics, Inc.
    Inventors: Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
  • Patent number: 10889807
    Abstract: The present disclosure describes a variant polypeptide having lipolytic activity, wherein the variant has an amino acid sequence which, when aligned with the amino acid sequence as set out in SEQ ID NO: 2, comprises at least one substitution of an amino acid residue at a position corresponding to any of the positions 113, 122, 138, 141, 179, 282, 284, 286, 295, said positions being defined with reference to SEQ ID NO: 2, and wherein said variant has at least 70% identity with the mature polypeptide having lipolytic activity as set out in SEQ ID NO: 2. Such a variant polypeptide may be used in the preparation of a baked product.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: January 12, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Rene Marcel De Jong, Chantal Christis, Neil Carr
  • Patent number: 10870839
    Abstract: The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having two, three, or more modifications as compared to a parent lipolytic enzyme and having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: December 22, 2020
    Assignee: DANISCO US INC
    Inventors: Thomas P. Graycar, Ayrookaran J. Poulose, David A. Estell
  • Patent number: 10858637
    Abstract: The present invention relates to isolated polypeptides with lipase activity. The invention also relates to polynucleotides encoding the polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; compositions comprising the polynucleotides and methods of using the polypeptides or the compositions.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: December 8, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Kenneth Jensen, Maria Louise Leth, Anna Verena Reiser, Robert Piotr Olinski, Preben Nielsen, Lone Baunsgaard
  • Patent number: 10858640
    Abstract: Disclosed is a method for production of recombinant human DNase I which is of such high purity as may be directly used as a medical drug. The method includes the steps of; culturing recombinant DNase I-producing mammalian cells, subjecting a culture supernatant to an anion-exchange column chromatography, subjecting to a column chromatography employing as solid phase a material having affinity for phosphate group, subjecting to a cation-exchange column chromatography, and subjecting to a dye affinity column chromatography.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 8, 2020
    Assignee: JCR PHARMACEUTICALS CO., LTD.
    Inventors: Yuri Koshimura, Miroslav Matev, Hiroyuki Sonoda
  • Patent number: 10801062
    Abstract: The present invention provides methods and systems for sequencing long nucleic acid fragments. In one aspect of the invention, methods, systems and reagent kits are provided for sequencing nucleic acid target sequences. Some embodiments of the methods, systems and reagent kits are particularly suitable for sequencing a large number of fragments, particularly long fragments.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: October 13, 2020
    Assignee: Centrillion Technology Holdings Corporation
    Inventors: Wei Zhou, Rui Mei, Filip Crnogorac, Guochun Liao, Julian Lucas
  • Patent number: 10760037
    Abstract: The present invention relates to a composition comprising: (a) a source of sulfite; and (b) a lipase variant of a parent lipase, wherein said variant has improved stability towards sulfite as compared to the parent lipase.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 1, 2020
    Assignee: NOVOZYMES A/S
    Inventors: Marco Malten, Thomas Agersten Poulsen, Lise Munch Mikkelsen, Dorte Marie Koefoed Klitgaard, Vibeke Skovgaard Nielsen, Katarina Larson
  • Patent number: 10758595
    Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: September 1, 2020
    Assignee: Precision BioSciences, Inc.
    Inventors: Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • Patent number: 10738305
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Matthew Hebden Porteus
  • Patent number: 10697015
    Abstract: The present invention relates to methods of genotyping for selecting an animal with a desired trait such as the level monounsaturated fats in muscle tissue, the types and/or ratio of different monounsaturated fats in muscle tissue, marbling, carcass weight, meat quality, speed of finishing, feedlot efficiency and/or consumer preference. In particular the invention relates to methods of selecting an animal with a desired trait by analysing the M-RIP, NT5M and/or TCAP genes for one or more polymorphisms.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 30, 2020
    Assignee: CY O'CONNOR ERADE VILLAGE FOUNDATION
    Inventors: Roger Letts Dawkins, John Anthony Millman, Joseph Frederick Williamson, Patrick Robert Carnegie
  • Patent number: 10689631
    Abstract: Unnatural, mutated thioesterases having an amino acid sequence that is at least 80% identical to SEQ ID NO:1 and having substitutions at one or more of amino acid positions I107, R108, L109, S122, M141, E142, Y145, and L146, gene constructs encoding and configured to express the mutated thioesterases in a transformed host cell, and host cells transformed to contain the gene constructs.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: June 23, 2020
    Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, THE PENN STATE RESEARCH FOUNDATION
    Inventors: Brian F. Pfleger, Nestor Jose Hernandez-Lozada, Costas Maranas, Matthew Grisewood
  • Patent number: 10683542
    Abstract: The invention pertains to construction of next-generation DNA sequencing (NGS) libraries for whole genome sequencing, targeted resequencing, sequencing-based screening assays, metagenomics, or any other application requiring sample preparation for NGS.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 16, 2020
    Assignee: INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Zachary Zwirko, Yu Zheng, Mirna Jarosz, Caifu Chen, Joseph Walder
  • Patent number: 10675302
    Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 9, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Fyodor Urnov
  • Patent number: 10648001
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Patent number: 10603363
    Abstract: Disclosed are recombinant meganucleases engineered to recognize and cleave recognition sequences present in a mutant RHO P23H allele. The invention further relates to the use of such recombinant meganucleases in methods for treating retinitis pigmentosa, wherein the mutant RHO P23H allele is preferentially targeted, cleaved, and inactivated.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 31, 2020
    Assignee: Precision BioSciences, Inc.
    Inventors: Victor Bartsevich, Derek Jantz, James Jefferson Smith, Michael G. Nicholson
  • Patent number: 10590479
    Abstract: A method for sequencing a nucleic acid is provided. In certain embodiments the method comprises obtaining a duplex comprising a nucleic acid and a primer, wherein the primer has a nuclease resistant 3? end, combining the duplex with a chain terminator nucleotide and a proof-reading polymerase to produce a reaction in which the polymerase idles on the added chain terminator nucleotide, identifying the chain terminator nucleotide added to the end of the primer; and adding a nuclease-resistant nucleotide to the end of the primer after the polymerase has idled on and removed the added chain terminator nucleotide, thereby producing a duplex comprising the template and an extended primer that has a nuclease resistant 3? end.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: March 17, 2020
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Brian Jon Peter, Joel Myerson
  • Patent number: 10584320
    Abstract: The present invention relates to novel esterase, more particularly to esterase variants having improved thermostability compared to the esterase of SEQ ID NO: 1 and the uses thereof for degrading polyester containing material, such as plastic products. The esterases of the invention are particularly suited to degrade polyethylene terephthalate, and material containing polyethylene terephthalate.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: March 10, 2020
    Assignee: CARBIOS
    Inventors: Christopher Topham, Helene Texier, Vincent Tournier, Marie-Laure Desrousseaux, Sophie Duquesne, Isabelle Andre, Sophie Barbe, Alain Marty
  • Patent number: 10465197
    Abstract: The present invention is an inducible coexpression system, capable of controlled induction of expression of each gene product.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 5, 2019
    Assignee: AbiSci, LLC
    Inventors: Sean McClain, Mark Valasek
  • Patent number: 10329546
    Abstract: The present invention provides lipolytic enzyme variants. Specifically, the present invention provides lipolytic enzyme variants having two, three, or more modifications as compared to a parent lipolytic enzyme and having at least one improved property. In addition, the present invention provides compositions comprising a lipolytic enzyme variant of the invention. The present invention also provides methods of cleaning using compositions comprising a lipolytic enzyme variant of the invention.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 25, 2019
    Assignee: DANISCO US INC
    Inventors: Thomas P. Graycar, Ayrookaran J. Poulose, David A. Estell
  • Patent number: 10238904
    Abstract: Disclosed herein are non-wild-type organophosphorus acid anhydrolases having two site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as ((RS)-Propan-2-yl methylphosphonofluoridate) (Sarin) and other organophosphorus compounds.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: March 26, 2019
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Mark A Guelta, Melissa M. Dixon, Steven P Harvey
  • Patent number: 10227622
    Abstract: The present invention provides for a genetically modified host cell comprising a 2-pyrrolidone synthase, or an enzymatically active fragment thereof, heterologous to the host cell.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: March 12, 2019
    Assignee: The Regents of the University of California
    Inventors: Jingwei Zhang, Jay D. Keasling
  • Patent number: 10208319
    Abstract: Disclosed herein are methods, compositions, and kits for high efficiency, site-specific genomic editing of cells for treating or preventing genetic blood disorders.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 19, 2019
    Assignees: President and Fellows of Harvard College, The Children's Medical Center Corporation
    Inventors: Kiran Musunuru, Chad A. Cowan, Derrick J. Rossi
  • Patent number: 10167489
    Abstract: Methods and compositions for the production of dielectric fluids from lipids produced by microorganisms are provided, including oil-bearing microorganisms and methods of low cost cultivation of such microorganisms. Microalgal cells containing exogenous genes encoding, for example, a sucrose transporter, a sucrose invertase, a fructokinase, a polysaccharide-degrading enzyme, a lipid pathway modification enzyme, a fatty acyl-ACP thioesterase, a desaturase, a fatty acyl-CoA/aldehyde reductase, and/or an acyl carrier protein are useful in manufacturing dielectric fluids.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 1, 2019
    Assignee: Corbion Biotech, Inc.
    Inventors: Scott Franklin, Walter Rakitsky, George Rudenko, Xinhua Zhao, Felipe Arana Rodriguez, Wenhua Lu, Janice Wee
  • Patent number: 10150985
    Abstract: Provided are methods of depleting a target nucleic acid from an initial collection of nucleic acids. Aspects of the methods include contacting the initial collection with a nucleic acid guided nuclease specific for the target nucleic acid in a manner sufficient to deplete the target nucleic acid from the initial collection. Depending on a given application, depletion of a target nucleic acid may vary, e.g., where depleting may include cleaving a target nucleic acid in, or selectively separating a target nucleic acid from, the initial collection of nucleic acids. Also provided are compositions and kits for practicing embodiments of the methods.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: December 11, 2018
    Assignee: Takara Bio USA, Inc.
    Inventors: Andrew Alan Farmer, Craig Betts, Nathalie Bolduc
  • Patent number: 10066027
    Abstract: Disclosed herein is a protein purification system and methods of using the system. In particular, disclosed is a split intein comprising an N-terminal intein segment, which can be immobilized, and a C-terminal intein segment, which has the property of being self-cleaving, and which can be attached to a protein of interest. Through the self-cleaving mechanism of the intein, the protein of interest can be purified.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Ohio State Innovation Foundation
    Inventors: David Webster Wood, Changhua Shi
  • Patent number: 10066219
    Abstract: Disclosed are nucleotide sequences encoding thioesterase enzymes, methods for their production, their use in methods to form thioesters, and their use in methods of screening for other wild type bacteria capable of producing said thioesterase enzymes. Also disclosed are compositions comprising thioesters produced by the methods disclosed herein.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: September 4, 2018
    Assignees: Givaudan SA, Utah State University, Wisconsin Alumni Research Foundation
    Inventors: Tarun Bhowmik, Jeff Broadbent, Dennis Welker, James Steele, Mateo Budinich
  • Patent number: 10011822
    Abstract: A phytase having improved thermostability is disclosed. The phytase has a modified amino acid sequence of SEQ ID NO: 2, wherein the modification is one of mutations A to D. The mutation A is to substitute amino acids at positions 143 and 262 with cysteine, the mutation B is to substitute amino acids at positions 259 and 312 with cysteine, the mutation C is to substitute amino acids at positions 205 and 257 with cysteine, and the mutation D is to substitute amino acids at positions 264 and 309 with cysteine.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: July 3, 2018
    Assignee: DONGGUAN APAC BIOTECHNOLOGY CO., LTD.
    Inventors: Tzu-Hui Wu, Ya-Shan Cheng, Hui-Lin Lai, Cheng-Yen Lin, Tsung-Yu Ko, Jian-Wen Huang, Chun-Chi Chen, Rey-Ting Guo
  • Patent number: 9976130
    Abstract: This invention is directed toward a non-wild-type organophosphorus acid anhydrolase enzyme having two site mutations, method of production, and method of use to more effectively degrade toxic organophosphorus compounds and, in particular, toxic chemical GD (3,3-Dimethylbutan-2-ylmethylphosphonofluoridate), than the wild type organophosphorus acid anhydrolase.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: May 22, 2018
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Mark A Guelta, Melissa M. Dixon, Steven P. Harvey
  • Patent number: 9963708
    Abstract: A recombinant vector enables independent expression of a foreign gene without interfering with a biological circuit of a host cell. A gene encoding a guanylyl cyclase, a gene encoding cGMP receptor protein, and a regulatory nucleotide sequence to which cGMP receptor protein binds, which are derived from a microorganism, are recombined in at least one plasmid. Using the recombinant vector, a foreign gene may be independently expressed without interfering with a biological circuit of a host cell.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: May 8, 2018
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Geun Joong Kim, Eun Bin Lee, Sung Hwan You
  • Patent number: 9963715
    Abstract: Disclosed herein are nucleases and methods of using these nucleases for alteration of a globin gene and generation of cells.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: May 8, 2018
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Philip D. Gregory, Dmitry Guschin, Michael C. Holmes, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Andreas Reik, Fyodor Urnov, Lei Zhang
  • Patent number: 9909109
    Abstract: The present invention relates to isolated lipase variants, comprising a substitution at one or more positions corresponding to positions I86D,E,N,Q, E87C, I90D,E,Q, and N92D,E,Q of the mature polypeptide of SEQ ID NO: 2, wherein the variant has lipase activity. In some embodiments the present invention relates to isolated polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; methods of producing the variants; and compositions comprising the variants. The present invention also relates to methods of obtaining lipase variants; methods of cleaning; and use of lipase variants for cleaning.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: March 6, 2018
    Assignee: NOVOZYMES A/S
    Inventors: Jakob Skjold-Joergensen, Jesper Vind, Allan Svendsen
  • Patent number: 9809787
    Abstract: The present invention relates a method of obtaining a detergent composition comprising introducing (a) a lipase variant of a parent lipase which variant has at least 60% sequence identity with SEQ ID NO: 2, a substitution at a position corresponding to D254 of the mature polypeptide of SEQ ID NO: 2 and has lipase activity and (b) an anionic surfactant, wherein said composition has increased stability in comparison with a corresponding composition comprising the parent lipase.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: November 7, 2017
    Assignee: NOVOZYMES A/S
    Inventors: Jesper Vind, Lise Munch Mikkelsen, Marco Malten, Allan Svendsen, Kim Borch
  • Patent number: 9790503
    Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: October 17, 2017
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Qi Zeng
  • Patent number: 9771566
    Abstract: The present invention relates to organophosphorous hydrolase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: September 26, 2017
    Assignee: Novozymes A/S
    Inventors: Bjarne G. Hansen, Lars Kobberoe Skov, Leonardo De Maria, Julie Bille Rannes
  • Patent number: 9713634
    Abstract: The present invention comprises a method of concentrating a composition comprising a polypeptide of interest and the use of such concentrated composition for the treatment of diseases in mammals, in particular by subcutaneous injection.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: July 25, 2017
    Assignee: Shire Pharmaceuticals Ireland Limited
    Inventor: Stefan Nilsson
  • Patent number: 9631185
    Abstract: Fusion-proteins containing an enzyme, preferably a feed or food enzyme, coupled to a gut surface-binding domain are presented. The fusion-proteins can be used to promote feed utilization in animals. In a particular example, a Fusion enzyme according to the invention comprising a gut-surface-binding polypeptide segment linked to a phytase show an increased resident time in the gut, which leads to an increased amount of time given to the enzyme to catalyse the corresponding reaction which finally leads to improved feed utilisation.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: April 25, 2017
    Assignee: NOVOZYMES A/S
    Inventors: Ghislain Schyns, Stephane Duval, Aurelie Brelin
  • Patent number: 9605245
    Abstract: The present invention relates to variant phytase enzymes and their use thereof.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 28, 2017
    Assignee: Fornia BioSoultions, Inc.
    Inventors: Goutami Banerjee, Khin Oo, Xiyun Zhang, Jie Yang, Yingxin Zhang
  • Patent number: 9539311
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: January 10, 2017
    Assignees: Novozymes A/S, Novozymes Inc.
    Inventors: Allan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Patent number: 9513289
    Abstract: The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.
    Type: Grant
    Filed: March 27, 2014
    Date of Patent: December 6, 2016
    Assignees: The United Sates of America, as Represented by the Department of Veterans Affairs, University of Utah Research Foundation
    Inventor: Matthew A. Movsesian
  • Patent number: 9447392
    Abstract: The present invention relates to isolated polypeptides having organophosphorous hydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 20, 2016
    Assignee: Novozymes A/S
    Inventors: Steffen Danielsen, Lars Kobberoee Skov, Ricardo Leite, Vincent Laize, M. Leonor Cancela Da Fonseca
  • Patent number: 9415092
    Abstract: Butyrylcholinesterase (BChE) polypeptide variants of the presently-disclosed subject matter have enhanced catalytic efficiency for (?)-cocaine, as compared to wild-type BChE. Pharmaceutical compositions of the presently-disclosed subject matter include a BChE polypeptide variant having an enhanced catalytic efficiency for (?)-cocaine. A method of the presently-disclosed subject matter for treating a cocaine-induced condition includes administering to an individual an effective amount of a BChE polypeptide variant, as disclosed herein, to lower blood cocaine concentration.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: August 16, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Wenchao Yang
  • Patent number: 9415122
    Abstract: A molecular probe for use in detecting, monitoring, and/or imaging cancer cells and/or cancer cell metastasis, migration, dispersal, and/or invasion includes a targeting agent and a detectable moiety. The targeting agent specifically binds to and/or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule that is expressed by a cancer cell or another cell in the cancer cell microenvironment.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 16, 2016
    Assignee: Case Western Reserve University
    Inventor: Susann Brady-Kalnay